EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-world effectiveness and safety of upadacitinib in moderate-to-severe rheumatoid arthritis: Subgroup analysis for 1-year outcomes of UPHOLD study in Gulf Cooperation Council

Rajaie Namas, Gamal Attia, Suad Hannawi, Yaser Ali, Bhavna Khan, Elham Barakat, Adeeba Al-Herz, Ibrahim Al Homood, Aqeel Muhanna, Sami Bahlas, Hala Dalle, Ahmed Wasfy Abdelaziz und 4 weitere

Arab Journal of Rheumatology · 2026-01 · 4 (1) · 15-24

DOI: 10.4103/ajr.ajr_22_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arab Journal of Rheumatology, online erschienen am 09.06.2026. Verfasst von Rajaie Namas und 15 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Rheumatoid arthritis (RA), a chronic autoimmune disease, is increasingly prevalent in the Middle East. Although treatment guidelines are informed by randomized controlled trials, real-world evidence on the long-term effectiveness and safety of Janus kinase inhibitors such as upadacitinib (UPA) in Gulf Cooperation Council (GCC) countries remains limited. OBJECTIVE: To evaluate the effectiveness and safety of long-term UPA 15 mg once daily in patients from GCC countries with moderate-to-severe RA, focusing on treatment targets and response maintenance in real-world settings. METHODOLOGY: This is a subgroup analysis of the UPHOLD trial (NCT04497597), a prospective, multicenter, noninterventional study. UPA-naïve adults with moderate-to-severe RA received UPA 15 mg once daily as monotherapy or combined with other disease-modifying antirheumatic drugs. Co-primary endpoints were DAS28-CRP remission (

Zitieren

APA

Namas, R., Attia, G., Hannawi, S., Ali, Y., Khan, B., Barakat, E., Al-Herz, A., Homood, I. A., Muhanna, A., Bahlas, S., Dalle, H., Abdelaziz, A. W., Nour, Y., Anwar, A., Hamad, T., & Attar, S. (2026). Real-world effectiveness and safety of upadacitinib in moderate-to-severe rheumatoid arthritis: Subgroup analysis for 1-year outcomes of UPHOLD study in Gulf Cooperation Council. Arab Journal of Rheumatology, 4(1), 15-24. https://doi.org/10.4103/ajr.ajr_22_25

Vancouver

Namas R, Attia G, Hannawi S, Ali Y, Khan B, Barakat E, et al. Real-world effectiveness and safety of upadacitinib in moderate-to-severe rheumatoid arthritis: Subgroup analysis for 1-year outcomes of UPHOLD study in Gulf Cooperation Council. Arab Journal of Rheumatology. 2026;4(1):15-24. doi:10.4103/ajr.ajr_22_25

BibTeX
@article{Namas2026,
  author = {Namas, Rajaie and Attia, Gamal and Hannawi, Suad and Ali, Yaser and Khan, Bhavna and Barakat, Elham and Al-Herz, Adeeba and Homood, Ibrahim Al and Muhanna, Aqeel and Bahlas, Sami and Dalle, Hala and Abdelaziz, Ahmed Wasfy and Nour, Yasser and Anwar, Ali and Hamad, Tharwat and Attar, Suzan},
  title = {Real-world effectiveness and safety of upadacitinib in moderate-to-severe rheumatoid arthritis: Subgroup analysis for 1-year outcomes of UPHOLD study in Gulf Cooperation Council},
  journal = {Arab Journal of Rheumatology},
  year = {2026},
  volume = {4},
  number = {1},
  pages = {15--24},
  doi = {10.4103/ajr.ajr_22_25}
}
Kostenlos starten →